Notizie AIOM – anno XV – Pagina 98

13 Gennaio 2017

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer

Ipilimumab increases antitumor T-cell responses by binding to cytotoxic T-lymphocyte antigen 4. We evaluated treatment with ipilimumab in asymptomatic or minimally symptomatic patients with chemotherapy-naive metastatic castration-resistant prostate cancer without visceral ...
Leggi tutto

13 Gennaio 2017

Web-app

Una nuova web-app gratuita, in otto lingue, per computer, tablet e smartphone sul tumore al seno è disponibile sul sito del Corriere della Sera in collaborazione con l'Associazione Italiana di Oncologia Medica (leggi e scarica). Strumento interattivo in due versioni, ...
Leggi tutto

13 Gennaio 2017

ASCO Clinical Practice Guideline Update: Integration of Palliative Care Into Standard Oncology Care

9 gennaio 2017 - As reported by Betty R. Ferrell, PhD, of the City of Hope Medical Center, and colleagues in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline update on the integration of palliative care into standard oncology care. This update ...
Leggi tutto

13 Gennaio 2017

Current Good Manufacturing Practice Requirements for Combination Products

Gennaio 2017 - This guidance describes and explains the final rule on CGMP requirements for combination products (final rule as codified in 21 CFR part 4) that FDA issued on January 22, 2013. Prior to issuance of the final rule, although CGMP regulations were in place to ...
Leggi tutto

13 Gennaio 2017

FDA Grants Priority Review to Frontline Pembrolizumab Combo for NSCLC

11 gennaio 2017 - The FDA has granted a priority review to a supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) in combination with pemetrexed plus carboplatin as a treatment for patients with metastatic or advanced non-squamous non–small ...
Leggi tutto

13 Gennaio 2017

Second Opinions From Medical Oncologists for Early-Stage Breast CancerPrevalence, Correlates, and Consequences

Advances in the evaluation and treatment of breast cancer have made the clinical decision-making context much more complex. A second opinion from a medical oncologist may facilitate decision making for women with breast cancer, yet little is known about second opinion use. ...
Leggi tutto

13 Gennaio 2017

Antineoplastic Treatment of Advanced-Stage Non–Small-Cell Lung Cancer: Treatment, Survival, and Spending (2000 to 2011)

Multiple agents for advanced non-small-cell lung cancer (NSCLC) have been approved in the past decade, but little is known about their use and associated spending and survival. Methods We used SEER-Medicare data for elderly patients with a new diagnosis of advanced-stage ...
Leggi tutto

13 Gennaio 2017

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

First-line chemotherapy for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma is associated with short response duration, poor survival, and high toxicity. This study assessed atezolizumab (anti-programmed death-ligand 1 ) as treatment ...
Leggi tutto

13 Gennaio 2017

9 gennaio 2017 – AIFA pubblica il 15° Rapporto Nazionale sulla Sperimentazione Clinica dei medicinali

13 Gennaio 2017

10 gennaio 2017 – “Meningite: cosa c’è da sapere”: vademecum Ministero Salute, AIFA e ISS

LAVORIAMO CON

News

TUMORE AL SENO: METASTASI SI DIFFONDONO COME GOCCE SU UNA SUPERFICIE. LA CAPACITÀ INVASIVA DIPENDE DALLA “FLUIDITÀ” DEL CANCRO

ONE HEALTH FOUNDATION: AL VIA IL PROGETTO IN 36 CENTRI ESTIVI IN ALBANIA. SULLA “NAVE DELLA SALUTE” SVOLTI PIU’ DI 550 TEST E VISITE MEDICHE

AL VIA LA TERZA EDIZIONE DELLA “NAVE DELLA SALUTE” ITALIA-ALBANIA. LA PREVENZIONE SALE A BORDO CON 17 MEDICI SPECIALISTI E 10 AMBULATORI

TOVORAFENIB È LA PRIMA TERAPIA MIRATA APPROVATA IN EUROPA NEL GLIOMA PEDIATRICO DI BASSO GRADO RECIDIVATO O REFRATTARIO, INDIPENDENTEMENTE DAL TIPO DI ALTERAZIONE DI BRAF

TOZORAKIMAB HA SODDISFATTO L’ENDPOINT PRIMARIO DELLO STUDIO DI FASE III MIRANDA NEI PAZIENTI CON BPCO

MIASTENIA GRAVIS, 15MILA PERSONE COLPITE IN ITALIA. “UN’INSTALLAZIONE IMMERSIVA PER COMPRENDERE LA VITA DEI PAZIENTI E AUMENTARE LA CONSAPEVOLEZZA”

MELANOMA, IN ITALIA POSSONO ESSERE “EREDITARI” 2.600 CASI L’ANNO. IMI: “LA PREVENZIONE SIA ANCHE ESAMI GENETICI E SORVEGLIANZA CUTANEA”

Notizie AIOM – anno XV

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer

Web-app

ASCO Clinical Practice Guideline Update: Integration of Palliative Care Into Standard Oncology Care

Current Good Manufacturing Practice Requirements for Combination Products

FDA Grants Priority Review to Frontline Pembrolizumab Combo for NSCLC

Second Opinions From Medical Oncologists for Early-Stage Breast CancerPrevalence, Correlates, and Consequences

Antineoplastic Treatment of Advanced-Stage Non–Small-Cell Lung Cancer: Treatment, Survival, and Spending (2000 to 2011)

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

9 gennaio 2017 – AIFA pubblica il 15° Rapporto Nazionale sulla Sperimentazione Clinica dei medicinali

10 gennaio 2017 – “Meningite: cosa c’è da sapere”: vademecum Ministero Salute, AIFA e ISS